日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)

I(b)期研究评估肿瘤内激动剂抗CD40（selicrelumab）联合抗PD-L1（atezolizumab）治疗难治性或复发性B细胞淋巴瘤患者的安全性和有效性（ITSELF试验）

期刊:ImmunoOncology and Technology
影响因子:
doi:10.1016/j.iotech.2025.101077
Alshatti, N; Lemonnier, F; Bachy, E; Lopez, J; Llamas, F; Damotte, D; Burron, B; Velut, Y; Mauduit, C; de Charette, M; Roussel, M; Palard, X; Marabelle, A; Huot, R
B细胞
肿瘤
T细胞
肿瘤免疫
淋巴瘤
CD40
PD-L1
细胞生物学
CD4
免疫/内分泌
发表日期：2026
文献求助 收藏

Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm

维奈托克-蛋白酶体抑制剂-地塞米松用于不适合接受治疗的浆细胞样树突状细胞肿瘤患者

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024014590
Khalife-Hachem, Sabine; Pages, Arnaud; Akoury, Elie; Bonnet, Sarah; Birsen, Rudy; Busquet, Clémence; Contejean, Adrien; Danu, Alina; de Botton, Stéphane; de Charette, Marie; Dumas, Pierre Yves; Jaccard, Arnaud; Marfaing-Koka, Anne; Willekens, Christophe; Deconinck, Eric; Ghez, David
树突状细胞
免疫/内分泌
细胞生物学
树突状细胞
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?

姑息治疗咨询能否提高血液系统恶性肿瘤患者姑息治疗的整合率？

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2021004369
Prod'homme, Chloé; Touzet, Licia; Pierrat, Magali; Chevalier, Luc; Lesaffre, Helene; Berthon, Celine; Coiteux, Valerie; Barbieux, Sarah; Beauvais, David; Bauschert, Loïc; De Charette, Marie; Goursaud, Laure; Manier, Salomon; Facon, Thierry
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy

隐藏或防御：淋巴瘤免疫逃逸的两种策略：对免疫疗法的潜在启示

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2017.184192
de Charette, Marie; Houot, Roch
淋巴瘤
免疫/内分泌
发表日期：2018
文献求助 收藏